NEJM at ESMO - Overall Survival with Pembrolizumab in Early-Stage Triple- Negative Breast Cancer

N Engl J Med. 2024 Nov 28;391(21):e52. doi: 10.1056/NEJMe2411492. Epub 2024 Sep 15.
No abstract available

Publication types

  • Editorial